title: Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2).
abstract: Chronic pain and prescription opioid abuse are extremely prevalent in the United States and worldwide. The consequences of opioid misuse can be life-threatening with significant morbidity and mortality, exacting a heavy toll on patients, physicians, and society. The risk for misuse of prescribed opioids is much higher in patients with chronic pain, especially those with concurrent substance use and /or mental health disorders. Several reasons can account for the occurrence of opioid abuse and misuse, including self-medication, use for reward, compulsive use related to addiction, and diversion for profit. There is a need, therefore, for therapeutic approaches that balance treating chronic pain, while minimizing risks for opioid abuse, misuse, and diversion. Chronic opioid therapy for chronic non-cancer pain has seen a dramatic increase throughout the past 2 decades in conjunction with associated increases in the abuse of prescribed opioids and accidental opioid overdoses. Consequently, a validated screening instrument that provides an effective and rational method for selecting patients for opioid therapy, predicting risk, and identifying problems once they have arisen, could be of enormous benefit in clinical practice. An instrument as such has the potential to attenuate the risk of iatrogenic addiction. Despite the recent introduction of various screening strategies and instruments, no single test or instrument can reliably and accurately predict those patients unsuitable for opioid therapy or pinpoint those requiring heightened degrees of surveillance and monitoring throughout their therapy. Current opioid abuse screening tactics include assessing premorbid and comorbid substance abuse; assessing aberrant drug-related behaviors; stratification of risk factors; and utilizing opioid assessment screening tools. Several authors have contributed numerous screening tools and instruments to aid the assessment of appropriate opioid therapy. Additional essential measures include urine drug testing, prescription practice monitoring programs, opioid treatment agreements, and implementing universal precautions. Presently accepted recommendations consist of a combination of strategies designed to stratify risk, to identify and to understand aberrant drug-related behaviors, and to tailor treatments accordingly. This manuscript, Part 2 of a 2 part update, builds on the 2012 opioid guidelines published in Pain Physician, and the 2016 guidelines released by the Centers for Disease Control and Prevention. It reviews screening, monitoring, and addressing opioid abuse and misuse in patients with chronic non-cancer pain. Opioids, misuse, abuse, chronic pain, prevalence, risk assessment, risk management, drug monitoring, aberrant drug-related behavior.
authors.forename: Alan D
authors.initials: AD
authors.lastname: Kaye
authors.affiliation: Department of Anesthesiology, Louisiana State University Health New Orleans.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Jones
authors.forename: Adam M
authors.initials: AM
authors.lastname: Kaye
authors.affiliation: Department of Anesthesiology, Tulane School of Medicine, New Orleans, LA.
authors.forename: Juan G
authors.initials: JG
authors.lastname: Ripoll
authors.affiliation: Dept. of Anesthesiology, Louisiana State University Health.
authors.forename: Donald E
authors.initials: DE
authors.lastname: Jones
authors.affiliation: Georgia Pain Care, Atlanta, GA.
authors.forename: Vincent
authors.initials: V
authors.lastname: Galan
authors.affiliation: Department of Anesthesiology, Tulane School of Medicine, New Orleans, LA.
authors.forename: Burton D
authors.initials: BD
authors.lastname: Beakley
authors.affiliation: Department of Anesthesiology, Tulane School of Medicine, New Orleans, LA.
authors.forename: Frank
authors.initials: F
authors.lastname: Calixto
authors.affiliation: Louisiana State University.
authors.forename: Jamie L
authors.initials: JL
authors.lastname: Bolden
authors.forename: Richard D
authors.initials: RD
authors.lastname: Urman
authors.forename: Laxmaiah
authors.initials: L
authors.lastname: Manchikanti
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use; D059350:Chronic Pain / Q000188:drug therapy*; D062787:Drug Overdose; D006801:Humans; D009293:Opioid-Related Disorders / Q000209:etiology; D015813:Substance Abuse Detection; D014481:United States
chemical_list: D000701:Analgesics, Opioid